Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis
Curr Rev Clin Exp Pharmacol. 2022 Apr 12. doi: 10.2174/2772432817666220412110720. Online ahead of print.ABSTRACTBACKGROUND: Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely used given their proven efficacy in the relapsing form of the disease, while recently Siponimod and Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 Disease-modifying drugs are approved by the FDA, while in 2012, only nine were in the market. From March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs highlights the need to update our knowledge about th...
Source: Pharmacological Reviews - April 14, 2022 Category: Drugs & Pharmacology Authors: Vasileios-Periklis Stamatellos Georgios Papazisis Source Type: research
Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis
Curr Rev Clin Exp Pharmacol. 2022 Apr 12. doi: 10.2174/2772432817666220412110720. Online ahead of print.ABSTRACTBACKGROUND: Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely used given their proven efficacy in the relapsing form of the disease, while recently Siponimod and Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 Disease-modifying drugs are approved by the FDA, while in 2012, only nine were in the market. From March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs highlights the need to update our knowledge about th...
Source: Pharmacological Reviews - April 14, 2022 Category: Drugs & Pharmacology Authors: Vasileios-Periklis Stamatellos Georgios Papazisis Source Type: research
Safety and Monitoring of the treatment with Disease-Modifying Therapies for Multiple Sclerosis
Curr Rev Clin Exp Pharmacol. 2022 Apr 12. doi: 10.2174/2772432817666220412110720. Online ahead of print.ABSTRACTBACKGROUND: Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely used given their proven efficacy in the relapsing form of the disease, while recently Siponimod and Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 Disease-modifying drugs are approved by the FDA, while in 2012, only nine were in the market. From March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs highlights the need to update our knowledge about th...
Source: Pharmacological Reviews - April 14, 2022 Category: Drugs & Pharmacology Authors: Vasileios-Periklis Stamatellos Georgios Papazisis Source Type: research
Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates
ConclusionAtrophy in RR-MS patients treated with NTZ is regional and targeting highly cognitive regions mainly of the subcortical gray matter and the cerebellum. The cerebellum atrophy was a marker of physical disability progression. NTZ did not accelerate the atrophy process in MS and may play a neuroprotective role by increasing the thalamus volume. (Source: Brain and Behavior)
Source: Brain and Behavior - April 10, 2022 Category: Neurology Authors: Arwa Rekik,
Mona Aissi,
Islem Rekik,
Mariem Mhiri,
Mahbouba Ayed Frih Tags: ORIGINAL ARTICLE Source Type: research
Clinical and radiological effectiveness of natalizumab extended dosage interval in patients with relapsing multiple sclerosis
CONCLUSIONS: EDI with NTZ maintains high clinical and activity effectiveness in MRI.PMID:35383874 | DOI:10.33588/rn.7408.2021311 (Source: Revista de Neurologia)
Source: Revista de Neurologia - April 6, 2022 Category: Neurology Authors: D A Garc ía-Estévez G P érez-Lorenzo M J Fern ández-Pérez C Cid-Rodr íguez G Ozaita-Arteche Source Type: research
